MX2013010670A - Derivados de benzo [b] [1, 4] oxazina como moduldores receptores de deteccion de calcio. - Google Patents

Derivados de benzo [b] [1, 4] oxazina como moduldores receptores de deteccion de calcio.

Info

Publication number
MX2013010670A
MX2013010670A MX2013010670A MX2013010670A MX2013010670A MX 2013010670 A MX2013010670 A MX 2013010670A MX 2013010670 A MX2013010670 A MX 2013010670A MX 2013010670 A MX2013010670 A MX 2013010670A MX 2013010670 A MX2013010670 A MX 2013010670A
Authority
MX
Mexico
Prior art keywords
benzo
calcium sensing
receptor modulators
sensing receptor
oxazin
Prior art date
Application number
MX2013010670A
Other languages
English (en)
Spanish (es)
Inventor
Sanjeev Anant Kulkarni
Manojkumar Ramprasad Shukla
Sarde Gangaram Ankush
Pachpute Dilip Vipul
Majid Bashir Sayyed
Mahadeo Bhaskar Tryambake
Chetan Sanjay Pawar
Ganesh Navinchandra Gote
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2013010670A publication Critical patent/MX2013010670A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2013010670A 2011-03-18 2012-03-16 Derivados de benzo [b] [1, 4] oxazina como moduldores receptores de deteccion de calcio. MX2013010670A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN367KO2011 2011-03-18
PCT/IB2012/051268 WO2012127388A1 (en) 2011-03-18 2012-03-16 Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Publications (1)

Publication Number Publication Date
MX2013010670A true MX2013010670A (es) 2013-12-06

Family

ID=54192843

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010670A MX2013010670A (es) 2011-03-18 2012-03-16 Derivados de benzo [b] [1, 4] oxazina como moduldores receptores de deteccion de calcio.

Country Status (16)

Country Link
US (1) US9464063B2 (cg-RX-API-DMAC7.html)
EP (1) EP2686306B1 (cg-RX-API-DMAC7.html)
JP (1) JP6033835B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140051846A (cg-RX-API-DMAC7.html)
CN (1) CN103459377B (cg-RX-API-DMAC7.html)
AP (1) AP2013007153A0 (cg-RX-API-DMAC7.html)
AU (1) AU2012232706B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013023914A2 (cg-RX-API-DMAC7.html)
CA (1) CA2829466A1 (cg-RX-API-DMAC7.html)
EA (1) EA024893B9 (cg-RX-API-DMAC7.html)
IL (1) IL228461A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013010670A (cg-RX-API-DMAC7.html)
PH (1) PH12013501899A1 (cg-RX-API-DMAC7.html)
SG (1) SG193331A1 (cg-RX-API-DMAC7.html)
WO (2) WO2012127388A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306837B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2817299T3 (pl) 2012-02-24 2019-12-31 Lupin Limited Podstawione związki chromanowe jako modulatory receptorów wapniowych
WO2013136288A1 (en) 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
WO2014033604A1 (en) 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
EP3039014A1 (en) 2013-08-28 2016-07-06 Lupin Atlantis Holdings SA Substituted naphthalene compounds as calcium sensing receptor modulators
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
JP6585167B2 (ja) 2014-10-03 2019-10-02 ノバルティス アーゲー Fgfr4阻害剤としての縮環二環式ピリジル誘導体の使用
CN104464530B (zh) * 2014-11-18 2017-08-25 深圳市华星光电技术有限公司 曲面型显示装置
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
JP6756925B2 (ja) 2017-01-11 2020-09-16 ロダン・セラピューティクス,インコーポレーテッド ヒストンデアセチラーゼの二環式阻害剤
SMT202200232T1 (it) 2017-08-07 2022-07-21 Alkermes Inc Inibitori biciclici di istone deacetilasi
AU2020415502A1 (en) * 2019-12-27 2022-07-14 Lupin Limited Pharmaceutical composition of CaSR modulators and methods and uses thereof
DK4090654T3 (da) * 2020-01-17 2025-09-08 Lupin Ltd Fremgangsmåder, processer og mellemprodukter til fremstilling af kromforbindelser

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109880A (zh) 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3,4-二氢-2h-1,4-苯并噁嗪衍生物、制备及其应用
FR2809396B1 (fr) * 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
CA2527203C (en) 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist
CA2608194A1 (en) * 2005-05-09 2006-11-16 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
ES2527058T3 (es) * 2005-05-19 2015-01-20 Astellas Pharma Inc. Derivado de pirrolidina o sus sales
KR101129868B1 (ko) 2006-10-04 2012-04-12 화이자 프로덕츠 인코포레이티드 칼슘 수용체 길항제로서의 피리도[4,3-d]피리미딘-4(3H)-온 유도체
MX2009003981A (es) * 2006-10-26 2009-04-27 Amgen Inc Agentes moduladores del receptor de calcio.
JPWO2008059854A1 (ja) * 2006-11-16 2010-03-04 アステラス製薬株式会社 ピペリジン誘導体またはその塩
US9487494B2 (en) 2007-11-23 2016-11-08 Leo Pharma A/S Cyclic hydrocarbon compounds for the treatment of diseases
JP5685941B2 (ja) 2008-10-03 2015-03-18 味の素株式会社 CaSRアゴニスト
US8791147B2 (en) 2008-10-08 2014-07-29 Amgen Inc. Calcium receptor modulating agents
WO2010090069A1 (ja) * 2009-02-05 2010-08-12 ヤンマー株式会社 Egr装置及びこれを備えたエンジン装置
JP2012528086A (ja) 2009-05-27 2012-11-12 レオ ファーマ アクティーゼルスカブ 新規のカルシウム感知受容体調節化合物およびその医薬用途
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体

Also Published As

Publication number Publication date
US9464063B2 (en) 2016-10-11
ZA201306837B (en) 2015-05-27
US20140018358A1 (en) 2014-01-16
CN103459377B (zh) 2016-09-07
SG193331A1 (en) 2013-10-30
EP2686306A1 (en) 2014-01-22
EA201370205A1 (ru) 2014-01-30
EA024893B1 (ru) 2016-10-31
BR112013023914A2 (pt) 2016-12-13
EP2686306B1 (en) 2017-01-04
IL228461A0 (en) 2013-12-31
AU2012232706B2 (en) 2016-12-15
WO2012127385A1 (en) 2012-09-27
EA024893B9 (ru) 2017-01-30
PH12013501899A1 (en) 2013-11-25
AU2012232706A1 (en) 2013-09-26
CN103459377A (zh) 2013-12-18
AP2013007153A0 (en) 2013-09-30
WO2012127388A1 (en) 2012-09-27
KR20140051846A (ko) 2014-05-02
CA2829466A1 (en) 2012-09-27
JP2014510097A (ja) 2014-04-24
JP6033835B2 (ja) 2016-11-30
NZ616676A (en) 2015-09-25

Similar Documents

Publication Publication Date Title
PH12013501899A1 (en) Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
BR112014020826A2 (pt) moduladores e métodos de uso
PH12013500831A1 (en) Oxazoline and isoxazoline derivatives as crac modulators
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
EP2916680A4 (en) DEVICES AND METHOD FOR ADJUSTING THE FIT OF SHOES
PH12014501079A1 (en) 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions
PH12014501891B1 (en) Substituted chroman compounds as calcium sensing receptor modulators
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
PH12016500312A1 (en) 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
IN2015MN00421A (cg-RX-API-DMAC7.html)
WO2013005168A3 (en) Cannabinoid receptor modulators
WO2012090179A3 (en) Isoquinoline derivatives as cannabinoid receptor modulators
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
UY34497A (es) Formas cristalinas de [(S)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida de ácido 2-(2-metilamino-pirimidin-4-il)-1H-indol-5-carboxílico.
ECSP088789A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
EP2799418A4 (en) PROCESS FOR PREPARING LYCOPINE INTERMEDIATE 3-METHYL-4,4-DIALKOXY-1-BUTALDEHYDE